Johnson and Johnson 2015 Annual Report Download - page 27

Download and view the complete annual report

Please find page 27 of the 2015 Johnson and Johnson annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 112

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112

During 2015, the Company advanced its pipeline with several regulatory submissions and approvals for new drugs and
additional indications for existing drugs as follows:
Product Name (Chemical
Name) Indication
US
Approv
EU
Approv
US
Filing
EU
Filing
DARZALEX™ (daratumumab) For the treatment of double refractory multiple myeloma ✓✓
EDURANT®(rilpiravine) For use in combination with other anti-retroviral agents, for the
treatment-naïve adolescent patients aged 12 to 18 years with
HIV-1 infection ✓✓
IMBRUVICA®(ibrutinib) Treatment of Waldenström’s Macroglobulinemia ✓✓
Treatment for patients with relapsed or refractory chronic
lymphocytic leukemia (CLL) or small lymphocytic lymphoma in
combination with bendamustine and rituximab ✓✓
For use in treatment-naïve patients with chronic lymphocytic
leukemia ✓✓
INVEGA TRINZA®(paliperidone
palmitate)
An atypical antipsychotic injection administered four times a year
for the treatment of schizophrenia ✓✓
INVOKAMET®XR (canagliflozin) A once-daily therapy combining fixed doses of canagliflozin and
metformin hydrochloride extended release for the treatment of
adults with type 2 diabetes ✓
PREZCOBIX®(darunavir/
cobicistat)
For use in combination with other antiretroviral medicinal products
for the treatment of human immunodeficiency virus (HIV-1) ✓
SIMPONI®(golimumab) Treatment of non-radiographic axial spondyloarthritis ✓
STELARA®(ustekinumab) For the treatment of adolescents with moderate-to-severe
psoriasis ✓
For the treatment of adult patients with moderately to severely
active Crohn’s disease ✓✓
VELCADE®(bortezomib) For use in combination with rituximab, cyclophosphamide,
doxorubicin and prednisone for the treatment of adult patients with
previously untreated mantle cell lymphoma ✓
YONDELIS®(trabectedin) For the treatment of patients with unresectable or metastatic
liposarcoma or leiomyosarcoma ✓
The Pharmaceutical segment achieved sales of $32.3 billion in 2014, representing an increase of 14.9% over the prior
year, with strong operational growth of 16.5% and a negative currency impact of 1.6%. U.S. sales were $17.4 billion, an
increase of 25.0%. International sales were $14.9 billion, an increase of 5.0%, which included 8.3% operational growth
and a negative currency impact of 3.3%. In 2013, Pharmaceutical segment sales included a positive adjustment to
previous estimates for Managed Medicaid rebates. This negatively impacted 2014 Pharmaceutical operational sales
growth by 0.8% as compared to the prior year. In 2014, sales of the Company’s Hepatitis C products, OLYSIO®/
SOVRIAD®(simeprevir) and INCIVO®(telaprevir), had a positive impact of 6.9% on the operational growth of the
Pharmaceutical segment.
Medical Devices Segment
The Medical Devices segment sales in 2015 were $25.1 billion, a decrease of 8.7% from 2014, which included an
operational decline of 1.4% and a negative currency impact of 7.3%. U.S. sales were $12.1 billion, a decrease of 1.0% as
compared to the prior year. International sales were $13.0 billion, a decrease of 14.8% as compared to the prior year, with
an operational decrease of 1.7% and a negative currency impact of 13.1%. The divestitures of the Ortho-Clinical
Diagnostics and the Cordis Businesses had a negative impact of 3.2% and 0.6%, respectively, on the worldwide
operational growth of the Medical Devices segment as compared to 2014.
Johnson & Johnson 2015 Annual Report •15